Startup radar: VCs on femtech startups worth watching

Femtech has been gaining more interest from venture investors in recent years. While a broader downturn in dealmaking has slowed investments this year, 70 startups have still managed to attract $375.1 million globally, according to PitchBook data.

The sector raised a record $2.5 billion in 2021, while 2022 was the second most active year ever with $1.5 billion invested.

"We saw an explosion of interest and investment in women's health over the last couple of years, and even with the economic downturn, you can't put that genie back in the bottle," RH Capital managing director Elizabeth Bailey said. "There has been a lot of activity at the seed stage, but now there is a growing need for later-stage VCs to pick up the mantle to help advance that early progress."

We spoke to four VCs active in the space to see which startups—both in and outside of their portfolios—they think will transform women’s health.

Elizabeth Bailey
Managing director, RH Capital (Boston)
AOA Dx (US) "AOA Dx is an RH Capital portfolio company that is developing a non-invasive liquid biopsy test to diagnose ovarian cancer using novel ganglioside biomarkers.  Ovarian cancer is known as the 'silent killer' for women because of the difficulty diagnosing at the earliest stages of the disease, and is currently lacking effective diagnostic tools.  With a dramatically more accurate test—especially at Stage I/II—AOA has the potential to transform ovarian cancer diagnosis and truly be life saving." Comanche Biopharma (US) "Comanche Biopharma is developing a novel treatment for preeclampsia, a life-threatening condition for women during pregnancy for which there are currently no therapies.  Because of the complexity around including pregnant women in clinical trials, there has been very little innovation in maternal health therapeutics. Comanche is using siRNA to tackle the leading cause of maternal death across the globe."

Cristina Ljungberg
Investing partner, The Case For Her (Stockholm)
Aquafit Intimate (Israel)

"Aquafit Intimate is a pioneering intimate wellness company providing women with self-care products and services. Aquafit's pure natural products are made of plant-based ingredients, free from vaginal irritants or toxins, and uniquely designed for the vaginal environment. Their products address the sexual wellness and intimacy needs of all women of any age and are especially relevant for the stages of menopause.

"Painful sex as the result of vaginismus, vulvodynia, menopause, chemo and radiation, etc, is a massively underserved market with a lack of appropriate products and services. The Aquafit Intimate, (an) intimate hydrogel trainer, is showing incredible results across hundreds of early customers.

"The Case for Her invested in Aquafit because we genuinely believe it is one of the few companies on the market that actually prioritizes women's sexual wellness and pleasure by addressing many of the causes of painful sex, giving long term relief. Aquafit not only provides treatment for existing conditions, but also serves as a preventative product backed by research."